We welcome the 2024 UN AMR High-Level Meeting Political Declaration, and the concrete commitments made. The biopharmaceutical industry has continued to advance R&D through the IFPMA BCR AMR Action Fund, contributed research on the urgency of revitalizing the antibiotic innovation ecosystem, and outlined pathways to improving access to both existing and new antibiotics. We also highlighted the concerning loss of AMR research expertise and reaffirm our commitment to engage in the HLM follow-up processes.
We reiterate our support for the WHO’s 2025–2035 AMR priorities and the urgent need to establish effective R&D incentives and sustainable access mechanisms ahead of the 2029 UN AMR HLM. We also welcome the revision of the AMR Global Action Plan and stand ready to provide our expertise, drawing on the growing body of evidence around the AMR burden and the solutions needed to address it.